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The aim of the present study was to evaluate how serum testosterone level (T) can affect urinary
continence and erectile function in patients undergoing radical prostatectomy (RP). We included
257 patients with clinically localized prostate cancer, those who had filled out preoperative quality
of life questionnaires (University of California, Los Angeles Prostate Cancer Index, International
Index of Erectile Function (IIEF)), and those who had T and total PSA sampled the day before
surgery. We calculated correlations between T and age, body mass index (BMI), PSA, urinary
function or bother (UF, UB) and sexual function or bother (SF, SB) and IIEF-5 in the whole
population and in sub-populations with normal (X10.4nmoll
 1) and low (o10.4ngml
 1) T using
Pearson’s and Spearman’s correlation coefficients. We evaluated differences in these parameters
between patients with low and normal Tusing the unpaired samples t-test and Mann–Whitney test,
and finally the correlation between UF and SF, UB and SB, and between PSA and T in the overall
population, and separately in patients with low and normal T using the Pearson’s correlation
coefficient. Mean preoperative T was 13.5nmoll
 1 and 23.7% of patients presented a low T. Mean
age, mean BMI and mean preoperative total PSA at RP were 64.3 years, 25.9kgm
 2 and 9.0ngml
 1,
respectively. BMI was negatively correlated with T in the overall population (r¼ 0.266; P¼0.02);
moreover, patients with normal T presented lower BMI compared with patients with low T (25.7 vs
27.6: P¼0.02). We found a significant correlation between SF scores and Tin patients with normal T
(r¼0.1777: P¼0.05). SF was significantly higher in patients with normal T compared with those
with low T (74.8 vs 64.8: P¼0.05). Furthermore, UF and UB were significantly correlated with SF
(r¼0.2544: Po0.01) and SB (r¼0.2512: P¼0.01), respectively, in men with normal T. Serum T was
significantly correlated with PSA in men with low T (r¼0.3874: P¼0.0029), whereas this correlation
was missed in the whole population and in men with normal T. The correlation between
preoperative PSA and T in men with low T is in agreement with the ‘saturation’ model proposed
by Morgentaler. The correlation between basal T and preoperative erectile function and urinary
continence underlines the importance of assessing T before RP.
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Introduction
The quality of life (QOL) of patients with prostate cancer
(PCa) is usually assessed to measure the safety and
tolerability of treatment outcomes,
1,2 to compare differ-
ent therapeutic approaches
3 or to monitor the progres-
sion of disease during time.
4
Moreover, several authors have reported that the
return of serum testosterone level (T) to normal range
during intermittent androgen deprivation is associated
with a significant improvement of general well-being,
and urinary (UF) and sexual function (SF).
5–7 In parti-
cular, QOL benefits in the off-treatment phase are shown
by a shift toward baseline levels in the scales depicting
physical and work functions, urgency, nocturia, impo-
tence and sexual performance.
8
Furthermore, hypogonadism is very common in elderly
men and men who have PCa: the symptoms of hypo-
gonadism, such as depression, erectile dysfunction (ED)
and lower urinary tract symptoms, can significantly
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9 In a recent retrospective study, such
as in several recent reviews, the authors suggested that
testosterone replacement therapy can be achieved in
hypogonadal men undergoing treatments for PCa.
10–13
The aim of the present study is to evaluate the in-
fluence of serum testosterone on urinary continence
and sexual activity in patients undergoing radical pros-
tatectomy (RP) for clinically localized PCa.
Materials and methods
Population
A total of 257 patients were consecutively selected for the
study. Inclusion criteria were as follows: having under-
gone RP as primary therapy for clinically localized PCa
(cT1–cT2, N0, M0); having preoperatively filled out the
QOL questionnaires (University of California, Los
Angeles Prostate Cancer Index (UCLA-PCI) and inter-
national index of erectile function (IIEF)); having
sampled the testosterone and total PSA levels the day
before surgery; and having obtained signed informed
consent. Patients treated with neoadjuvant hormone or
radiotherapy, with missing data, with an inability to
complete the questionnaire and refusal to participate,
without preoperative testosterone or PSA, were excluded
from the trial.
Age, body mass index (BMI; weight/height
2), testo-
sterone and PSA were preoperatively recorded at about
0800 hours in a recovery regiment the day before the RP.
HRQOL measures
Informed consent was obtained from all subjects. This
trial was carried out in accordance with the ethical
principles of the Helsinki Declaration (1996) and Good
Clinical Practice Issues (1997) and was reviewed and
approved by both the local ethics committees.
We used the validated Italian version of the UCLA-PCI
and the IIEF-5 to assess urinary and sexual QOL
condition. UCLA-PCI allows evaluation of the detailed
symptoms as well as their corresponding bother. For this
analysis, we focused on subject UF and SF and urinary
and sexual bother (UB and SB). Responses were scored
from 0 to 100, with a higher score indicating better
QOL.
14
IIEF was used to better define the erectile function. The
possible scores for the IIEF-5 range from 5 to 25, and ED
was classified into five categories based on the scores:
severe (5–7), moderate (8–11), mild to moderate (12–16),
mild (17–21) and no ED (22–25).
15
Statistics
We calculated the correlations between T and age, BMI,
PSA, UF, UB, SF, SB and IIEF-5 in the whole population
and in both the subpopulations of men with normal
(TX10.4nmoll
 1) and low (To10.4ngml
 1) serum T
using the Pearson’s correlation coefficient and Spear-
man’s correlation coefficient (see Table 1).
Moreover, we evaluated the differences in age, BMI,
PSA, UF, UB, SF, SB and IIEF-5 between patients with
To10.4nmoll
 1 and TX10.4nmoll
 1 using an unpaired
samples t-test and a Mann–Whitney test (see Table 2).
Finally, we evaluated the correlation between UF and
SF, UB and SB, and the correlation between PSA and
testosterone in the overall population and separately in
patients with low and normal T using the Pearson’s
correlation coefficient (see Figures 1 and 2).
Results
Mean preoperative T was 13.5nmoll
 1 (median
13.2nmoll
 1, range 0.5–29): 61 patients (23.7%) had a
To10.4nmoll
 1. Mean age at RP was 64.3 years (median
67, range 45–76). Mean BMI was 25.9kgm
 2 (median
25.5, range 17.7–34.6): 10 subjects (3.9%) had BMI
o20kgm
 2, 90 (35.0%) between 20 and 24.9kgm
 2 and
157 (61.1%) above 25kgm
 2. Mean preoperative total
PSA was 9.0ngml
 1 (median 7.6, range 0.6–48.8): 187
(72.7%) had a PSA o10ngml
 1, 53 (20.6%) between 10–
20ngml
 1 and 17 (6.6%) above 20ngml
 1. Mean UCLA-
PCI and IIEF scores in the overall population and in
patients with normal and low T are reported in Table 2.
We did not report any significant results from the
analyses of age. BMI was negatively correlated with T in
the overall population (see Table 1: P¼0.02); moreover,
patients with normal T presented lower BMI compared
with patients with T below 10.4nmoll
 1 (see Table 2: 25.7
vs 27.6kgm
 2, P¼0.02).
We evidenced a significant correlation between SF
scores and T in patients with T above 10.4nmoll
 1 (see
Table 1: P¼0.05). Moreover, SF was significantly higher
in patients with normal T compared with patients with
low T (see Table 2: 74.8 vs 64.8; P¼0.05). The remaining
UCLA-PCI items (UF, UB, SB) and the IIEF questionnaire
were statistically insignificant in all the analyses.
Table 1 Correlations between testosterone and age, BMI, PSA, UF, UB, SF, SB (items from UCLA-PCI) and IIEF-5 in the whole population
(overall) and in both the subpopulations of hypogonadal (To10.4) and eugonadal (TX10.4) men using Pearson’s and Spearman’s correlation
coefficients
No. of pts (%) Age
a BMI
a PSA
a UF UB SF SB IIEF
a
Overall 257 r¼0.033,
P¼0.6024
r¼ 0.266,
P¼0.0213
r¼ 0.035,
P¼0.5802
r¼0.0173,
P¼0.8479
r¼ 0.1000,
P¼0.2670
r¼ 0.0297,
P¼0.7444
r¼0.0102,
P¼0.9107
r¼ 0.054,
P¼0.4540
To10.4 61 (23.7) r¼0.054,
P¼0.6850
r¼ 0.121,
P¼0.6623
r¼0.360,
P¼0.0066
r¼ 0.0318,
P¼0.8912
r¼ 0.1281,
P¼0.5799
r¼0.1179,
P¼0.6308
r¼0.3769,
P¼0.1117
r¼0.124,
P¼0.4326
TX10.4 196 (76.3) r¼0.043,
P¼0.5546
r¼ 0.100,
P¼0.4335
r¼ 0.107,
P¼0.1396
r¼0.0682,
P¼0.4895
r¼ 0.0552,
P¼0.5779
r¼0.1777,
P¼0.0511
r¼0.1360,
P¼0.1686
r¼0.026,
P¼0.7507
Abbreviations: BMI, body mass index; IIEF, International Index of Erectile Function; SB, sexual bother; SF, sexual function; UB, urinary bother; UCLA-PCI, University
of California Los Angeles Prostate Cancer Index; UF, urinary function.
aCalculated using Spearman’s correlation coefficient. Bold entries are data with statistical significance.
Influence of testosterone on urinary continence and sexual activity
M Gacci et al
169
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(r¼0.2544; Po0.01, see Figure 1), such as UB with SB
(r¼0.2512 P¼0.01) in men with TX10.4nmoll
 1. We did
not find significant correlation between UF and SF and
between UB and SB in the overall population (UF–SF:
r¼0.1639; P¼0.0677; UB–SB: r¼0.1525; P¼0.0896),
and in men with low T (UF–SF: r¼ 0.2412; P¼0.3199;
UB–SB: r¼ 0.3458; P¼0.1470).
Finally, serum testosterone was significantly correlated
with PSA levels in men with To10.4nmoll
 1 (r¼0.3874;
P¼0.0029), whereas this correlation was missed in the
whole population (r¼0.0038; P¼0.9522) and in men with
T410.4nmoll
 1 (r¼ 0.0880; P¼0.2249, see Figure 2).
Discussion
PSA levels in hypogonadal men are often low and after
testosterone replacement therapy they normalize, but do
not continue to increase with ongoing therapy.
16
In healthy volunteers, medical castration, although
dramatically reducing serum testosterone and dihydro-
testosterone levels, does not abolish intraprostatic levels,
and they remain at 20–30%. This may indicate that there
is a capacity within the prostate to manufacture and
rogens in the face of very low plasma levels.
17
The association between PSA and testosterone levels
is not completely clarified. In this paper, we des-
cribed a significant association between PSA and T
only in hypogonadal men (To10.4nmoll
 1), whereas
this correlation was not evident in men with normal T
(T410.4nmoll
 1).
These data are in agreement with the ‘saturation’
model proposed by Morgentaler and Traish.
1 According
to this model, the human prostate is sensitive to massive
androgen ablation but rather insensitive in normal or
even in subnormal conditions (as in late-onset hypo-
gonadism). This hypothesis has recently been confirmed
in a large series of individuals consulting for ED:
18 in
particular it has been reported that PSA is androgen-
dependent only in the youngest hypogonadal men,
whereas this correlation disappears with higher levels
of androgenization. Therefore, here we reported the
same correlation in patients with PCa even if there is
no evidence to support testosterone as a ‘cause’ of PCa.
In this study, we did not analyze SHBG levels. However,
in our set of analyses we could not evaluate the role of
free testosterone in both urinary continence and in the
setting of PCa. Further evaluation regarding this should
be considered in future studies with the aim of limiting
the overall cost of the trial.
Moreover, we demonstrated in a population of
patients undergoing RP for PCa that men with low T
presented significantly worse erectile function (lower SF
score) compared with men with normal T: in addition, in
eugonadal patients T was positively correlated with
sexual activity. Even though the association between T
and erectile function has not been completely clarified
19–20
and the role of T in PCa development is still under
investigation,
21,22 our study investigated the relation-
ship between T and ED in men with PCa, before RP.
Our data seem to be in agreement with the conclu-
sions of Khera,
23 suggesting that although the relation-
ship between testosterone and improvement in erectile
function should be well established, the role of testo-
sterone in ED recovery after RP may be of even greater
significance.
Table 2 Differences in age, PSA, UF, UB, SF, SB and IIEF-5 between hypogonadal (To10.4) and eugonadal (TX10.4) men: mean value
according to groups, and levels of significance (To10.4 vs TX10.4) using the unpaired samples t-test and Mann–Whitney test
No. of pts (%) Age
a BMI
a PSA
a UF UB SF SB IIEF
a
Overall 257 64.3 25.9 9.0 94.9 92.4 72.9 71.6 19.4
To10.4 61 (23.7) 64.1 27.6 8.9 96.1 95.2 64.8 61.8 18.2
TX10.4 196 (76.3) 64.3 25.7 9.0 94.5 91.6 74.8 73.6 19.5
PP ¼0.8888 P¼0.0118 P¼0.8920 P¼0.5905 P¼0.3423 P¼0.0543 P¼0.1608 P¼0.4155
Abbreviations: BMI, body mass index; IIEF, International Index of Erectile Function; SB, sexual bother; SF, sexual function; UB, urinary bother; UF, urinary
function.
aCalculated using Mann–Whitney test. Bold entries are data with statistical significance.
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Figure 1 Correlation between urinary function (UF) and sexual
function (SF) in men with TX10.4nmoll
 1. Pearson’s correlation
coefficient: r¼0.2544; P¼0.0095.
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Figure 2 Correlation between testosterone and PSA in men with
To10.4nmoll
 1). Pearson’s correlation coefficient: r¼0.3874;
P¼0.0029.
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Prostate Cancer and Prostatic DiseasesBeyond the well-known role of T in regulating nitric
oxide formation, recent experimental evidences have
shown that T also regulates the expression of phospho-
diesterase type 5 (PDE5).
24,25 As T positively controls
both the initiation (nitric oxide synthase) and the end
(PDE5) of the erectile process, its net effect on erection
is modest. Hence, erections are still possible in hypo-
gonadal conditions, in which a decreased cyclic guanosine
monophosphate formation, owing to impaired nitric oxide
production, is most probably counterbalanced by a reduced
PDE5 activity and cyclic guanosine monophosphate hydro-
lysis.
26 Therefore, the main physiological action of T
is to timely adjust the erectile process as a function
of sexual desire, finalizing erections to sex. Moreover,
a trophic effect of T on penile architecture has also
been shown by in vivo data in different animal species
and ex vivo data extrapolated from rabbits.
24,27 For all
the aforementioned reasons, treatment of hypogonadism
restores impaired penile erections in experimental animal
models, as well as in the clinical setting. Conversely,
administration of testosterone to otherwise eugonadal
individuals is ineffective.
19
Finally, a significant result of our study is the strong
correlation between urinary symptoms and SF (UF vs SF:
P¼0.0095) in eugonadal men, and the lack of this
correlation in hypogonadal men. This finding is in line
with our published studies: as we previously showed
in an in vitro study on the human bladder, PDE5 is
expressed not only in the smooth muscle cells of the
bladder wall but also in the endothelial and smooth
muscle cells of the vessels.
28 We also showed that the
continence recovery after nerve-sparing prostatectomy
for PCa was strictly correlated with recovery of SF: thus,
we concluded that PDE5 inhibitors can exhibit an activity
in the lower urinary tract, even in the absence of the
prostatic gland, by a pathway not including prostate.
29
Therefore, the androgen-dependent PDE5 activity of the
bladder wall can explain the significant correlation
between erectile function and urinary symptoms exclu-
sively in patients with adequate T. In our experience, this
activity can be provided both by the relaxation of the
smooth muscle and by the improvement in perfusion of
the bladder wall.
30
Conclusion
We demonstrated a significant association between
preoperative PSA and testosterone in men with low T
(To10.4nmoll
 1) levels before prostatectomy, and this
correlation was not evident in men with normal T.
Moreover, we showed that before RP men with low T
presented significantly worse erectile function (lower SF
scores) compared with men with normal T, and that T is
positively correlated with erectile function when it is
410.4nmoll
 1.
Finally, men with normal T preoperatively presented a
strong correlation between their urinary continence and
sexual activity.
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